Annals of Clinical and Translational Neurology (Jul 2019)

Identification of serum microRNAs as potential biomarkers in Pompe disease

  • Ana Carrasco‐Rozas,
  • Esther Fernández‐Simón,
  • Maria Cinta Lleixà,
  • Izaskun Belmonte,
  • Irene Pedrosa-Hernandez,
  • Elena Montiel-Morillo,
  • Claudia Nuñez‐Peralta,
  • Jaume Llauger Rossello,
  • Sonia Segovia,
  • Noemí De Luna,
  • Xavier Suarez‐Calvet,
  • Isabel Illa,
  • Pompe Spanish Study group,
  • Jordi Díaz‐Manera,
  • Eduard Gallardo

DOI
https://doi.org/10.1002/acn3.50800
Journal volume & issue
Vol. 6, no. 7
pp. 1214 – 1224

Abstract

Read online

Abstract Objective To analyze the microRNA profile in serum of patients with Adult Onset Pompe disease (AOPD). Methods We analyzed the expression of 185 microRNAs in serum of 15 AOPD patients and five controls using microRNA PCR Panels. The expression levels of microRNAs that were deregulated were further studied in 35 AOPD patients and 10 controls using Real‐Time PCR. Additionally, the skeletal muscle expression of microRNAs which showed significant increase levels in serum samples was also studied. Correlations between microRNA serum levels and muscle function test, spirometry, and quantitative muscle MRI were performed (these data correspond to the study NCT01914536 at ClinicalTrials.gov). Results We identified 14 microRNAs that showed different expression levels in serum samples of AOPD patients compared to controls. We validated these results in a larger cohort of patients and we found increased levels of three microRNAs, the so called dystromirs: miR‐1‐3p, miR‐133a‐3p, and miR‐206. These microRNAs are involved in muscle regeneration and the expression of these was increased in patients' muscle biopsies. Significant correlations between microRNA levels and muscle function test were found. Interpretation Serum expression levels of dystromirs may represent additional biomarkers for the follow‐up of AOPD patients.